Welcome to our dedicated page for Embecta SEC filings (Ticker: EMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Embecta Corp. (EMBC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its operations as a global diabetes care and medical supplies company. As an issuer listed on The Nasdaq Global Select Market, embecta’s SEC filings cover topics such as financial performance, governance, compensation, and material corporate events.
On this page, you can review current reports on Form 8-K, where embecta discloses items like quarterly and full-year financial results, dividend declarations, and changes to its board of directors. For example, the company has used Form 8-K to report earnings for specific quarters and fiscal years, and to describe director departures and planned leadership changes on the board.
Embecta also files a definitive proxy statement on Schedule 14A, which outlines proposals for its annual meeting of stockholders, including the election of directors, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and amendments to equity-based compensation plans. The proxy statement provides information on board composition, committee structures, director skills and experience, and governance practices.
In addition to these filings, investors can access embecta’s annual and quarterly reports referenced in its proxy materials, which contain audited financial statements, segment and product family revenue breakdowns, and discussions of strategic priorities such as strengthening the core business, expanding the product portfolio, and increasing financial flexibility.
Stock Titan’s platform enhances these regulatory disclosures with AI-powered summaries that highlight key points from lengthy documents, helping readers understand the implications of embecta’s 8-Ks, proxy statements, and other filings. Real-time updates from EDGAR, combined with structured access to forms related to governance and financial reporting, allow users to follow how embecta’s strategy, board decisions, and financial performance are reflected in its official SEC record.
Embecta Corp — The Vanguard Group filed Amendment No. 5 to a Schedule 13G/A reporting zero beneficial ownership of Embecta Corp common stock, listing 0 shares and 0% ownership. The filing states this reporting change follows an internal realignment of Vanguard and related subsidiaries in accordance with SEC Release No. 34-39538.
The amendment identifies Vanguard's separate reporting by subsidiaries and notes that The Vanguard Group, Inc. no longer is deemed to have beneficial ownership over securities held by those subsidiaries. The form is signed by a Vanguard official on 03/26/2026.
Embecta Corp. has agreed to acquire UK-based medical device maker Owen Mumford Holdings Limited in a transaction valued at up to £150 million. Embecta will pay £100 million in cash at closing, plus up to £50 million in additional payments tied to net sales of the Aidaptus® auto-injector platform through the three-year period following closing.
Owen Mumford generated net revenue of £69.4 million during its fiscal year 2025 and brings a portfolio of drug-delivery and chronic care devices that complement Embecta’s diabetes-focused franchise. Embecta expects the deal to support revenue growth from fiscal year 2027 onward, be accretive to adjusted operating income after fiscal year 2027, and generate a high-single-digit return on invested capital by year four.
The transaction, unanimously approved by Embecta’s board, is structured as a share acquisition for 100% of Owen Mumford’s equity and is expected to close in Embecta’s fiscal third quarter of 2026, subject to regulatory approvals and customary conditions. Embecta plans to fund the upfront purchase price with borrowings under its revolving credit facility.
Anderson Carrie L reported acquisition or exercise transactions in a Form 4 filing for EMBC. The filing lists transactions totaling 22,841 shares. Following the reported transactions, holdings were 64,581 shares.
HOMBACH ROBERT J. reported acquisition or exercise transactions in this Form 4 filing.
Embecta Corp. director Robert J. Hombach received an award of 22,841 shares of Embecta common stock on February 11, 2026 at a grant price of $0.00 per share. Following this grant, he directly beneficially owns 64,587.208 shares, which the filing notes include shares received as stock dividends.
Embecta Corp. director Morris Milton Mayo reported acquiring 22,841 shares of Embecta common stock on February 11, 2026. The shares were received as a grant or similar award at a price of $0.00 per share, meaning no cash was paid for the acquisition. Following this transaction, Mayo directly beneficially owns 60,121.34 Embecta common shares. The reported total includes shares that were received as stock dividends, so it reflects both prior holdings and dividend-related share accruals.
Embecta Corp. director Karen Prange reported an acquisition of 22,841 shares of common stock on February 11, 2026, as a grant or other award at a price of $0.00 per share. Following this transaction, she directly beneficially owned 64,581.208 shares. A footnote explains that the number of shares reported after the transaction includes shares she received as stock dividends.
Embecta Corp. director Claire Pomeroy reported an acquisition of 22,841 shares of common stock on February 11, 2026 as a grant, award, or other acquisition at a price of $0.00 per share. Following this transaction, she directly beneficially owns 66,127.164 shares. This total includes shares received as stock dividends.
Reidy Christopher R reported acquisition or exercise transactions in a Form 4 filing for EMBC. The filing lists transactions totaling 22,841 shares. Following the reported transactions, holdings were 70,122 shares.
Embecta Corp. reported the results of its 2026 Annual Meeting of Stockholders. All seven board nominees were elected to one-year terms, each receiving more than 45 million votes in favor, with several directors exceeding 48 million "For" votes.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026 with 53,083,728 votes in favor. On an advisory basis, stockholders approved executive compensation, and they approved an amendment to the 2022 Employee and Director Equity-Based Compensation Plan with 41,396,703 votes for and 7,034,781 against.
Embecta Corp. reported essentially flat revenue of $261.2M for the quarter ended December 31, 2025, down slightly from $261.9M a year earlier, but significantly higher profitability. Gross margin improved to 61.9%, lifting operating income to $83.3M from $28.7M.
Net income reached $44.1M versus break-even in the prior-year period, driven by lower research and development and restructuring costs and a $10.1M gain on the sale of patch pump intellectual property and assets. Operating cash flow was $17.2M, and cash and equivalents and restricted cash totaled $204.4M.
Embecta reduced its Term Loan by $37.5M in the quarter, leaving total principal debt of $1,379.3M and a weighted average borrowing cost of 6.1%. The company, a global diabetes injection-device provider, continues to face pricing pressure, shifting diabetes treatment patterns and macroeconomic uncertainty but reports compliance with all debt covenants.